LETTER : Difficult choices over MS drug

Dr Julie Woodin,Others
Friday 15 March 1996 00:02 GMT
Comments

Your support helps us to tell the story

This election is still a dead heat, according to most polls. In a fight with such wafer-thin margins, we need reporters on the ground talking to the people Trump and Harris are courting. Your support allows us to keep sending journalists to the story.

The Independent is trusted by 27 million Americans from across the entire political spectrum every month. Unlike many other quality news outlets, we choose not to lock you out of our reporting and analysis with paywalls. But quality journalism must still be paid for.

Help us keep bring these critical stories to light. Your support makes all the difference.

Sir: Polly Toynbee's article (11 March) gives the impression that Nottingham health authority's decisions relating to the use of beta- interferon are purely motivated by the need to cut costs. The reality is more complex.

We consulted the local MS groups, GPs, consultants, the community health council, the medical advisory committee and the drug company itself. We also took account of the results of the drug over the five-year trials. After giving full consideration to these views, we decided to put extra funding into the local neurological services in the next year. This will enable more effective treatments to be made available to patients.

Your contention that our public consultation meeting was in some way our response to a "row", that it was to explain why patients couldn't have the drug and that it was only as a result that the health authority found "extra money" is inaccurate. The public meeting was planned to take place following the issue of guidance by the Government. No decision had been taken before the meeting and the meeting directly informed our decision. This was always the planned sequence of events.

There will never be sufficient funds to meet all demands. But we shared these facts in public debate to gain the perspectives of the community and support the clinicians who face the hard decision of selecting the most appropriate patients.

Dr Julie Woodin

Chief Executive

Nottingham Health Authority

David Edwards

Chief Executive

Queen's Medical Centre,

University Hospital NHS Trust

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in